ArticleMedical care2013
Identifying specific chemotherapeutic agents in Medicare data: a validation study.
Article in Medical care, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- Do community-based patient assistance programs affect the treatment and well-being of patients with breast cancer?Journal of oncology practice · 2014Trial
- Quality of Treatment Selection for Medicare Beneficiaries With Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Association of platinum-based chemotherapy with live birth and infertility in female survivors of adolescent and young adult cancer.Fertility and sterility · 2024Article
- Maternal comorbidity and adverse perinatal outcomes in survivors of adolescent and young adult cancer: A cohort study.BJOG : an international journal of obstetrics and gynaecology · 2023Article
- Disparities in post-operative surveillance testing for metastatic recurrence among colorectal cancer survivors.Journal of cancer survivorship : research and practice · 2022Article
- Opportunities for personalizing colorectal cancer care: an analysis of SEER-medicare data.The pharmacogenomics journal · 2022Article
- Long-term antimüllerian hormone patterns differ by cancer treatment exposures in young breast cancer survivors.Fertility and sterility · 2022Article
- Article
- Survival of patients newly diagnosed with colorectal cancer and with a history of previous cancer.Cancer medicine · 2021Article
- Survival of women diagnosed with breast cancer and who have survived a previous cancer.Breast cancer research and treatment · 2021Article
- Association of immune-checkpoint inhibitors and the risk of immune-related colitis among elderly patients with advanced melanoma: real-world evidence from the SEER-Medicare database.Therapeutic advances in drug safety · 2021Article
- Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer.World journal of gastrointestinal oncology · 2020Review
- Assessing Cancer Treatment Information Using Medicare and Hospital Discharge Data among Women with Non-Hodgkin Lymphoma in a Los Angeles County Case-Control Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- Development and Utility of the Observational Research in Oncology Toolbox: Cancer Medications Enquiry Database-Healthcare Common Procedure Coding System (HCPCS).Journal of the National Cancer Institute. Monographs · 2020Article
- Assessment of Oncology Practice Billing Claims for Supplementing Chemotherapy: A Pilot Study in the Georgia SEER Cancer Registry.Journal of the National Cancer Institute. Monographs · 2020Article
- Utilization of the Cancer Medications Enquiry Database (CanMED)-National Drug Codes (NDC): Assessment of Systemic Breast Cancer Treatment Patterns.Journal of the National Cancer Institute. Monographs · 2020Article
- An Evaluation of the Utility of Big Data to Supplement Cancer Treatment Information: Linkage Between IQVIA Pharmacy Database and the Surveillance, Epidemiology, and End Results Program.Journal of the National Cancer Institute. Monographs · 2020Article
- Concordance Between Electronic Health Record Data and Medicare Part D Claims Data for Oral Anticancer Drug Use.JAMA network open · 2020Article
- Geriatric oncology health services research: Cancer and Aging Research Group infrastructure core.Journal of geriatric oncology · 2020Article
- Evaluating Surveillance Patterns after Chemoradiation-Only Compared with Conventional Management for Older Patients with Rectal Cancer.Journal of the American College of Surgeons · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundLarge health care databases are increasingly used to examine the dissemination and benefits and harms of chemotherapy treatment in routine practice, particularly among patients excluded from trials (eg, the elderly). Misclassification of chemotherapy could bias estimates of frequency and association, warranting an updated assessment.
methodsWe evaluated the validity of Medicare claims to identify receipt of chemotherapy and specific agents delivered to elderly stage II/III colorectal (CRC), in situ/early-stage breast, non-small-cell lung, and ovarian cancer patients using the National Cancer Institute's Patterns of Care studies (POC) as the gold standard. The POC collected data on chemotherapy treatment by reabstracting hospital records, contacting physicians, and reviewing medical records. Patients' POC data were linked and compared with their Medicare claims for 2 to 12 months postdiagnosis. κ, sensitivity, specificity, positive and negative predictive values and 95% confidence intervals were calculated for the receipt of any chemotherapy and specific agents.
resultsSensitivity and specificity of Medicare claims to identify any chemotherapy were high across all cancer sites. We found substantial variation in validity across agents, by site and administration modality. Capecitabine, an oral CRC treatment, was identified in claims with high specificity (98%) but low sensitivity (47%), whereas oxaliplatin, an intravenously administered CRC agent had higher sensitivity (75%) and similar specificity (97%).
conclusionsReceipt of chemotherapy and specific intravenous agents can be identified using Medicare claims, showing improvement from prior reports; yet, variation exists. Future studies should assess newly approved agents and the impact of coverage decisions for these agents under the Medicare Part D program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.